Special Issue

Oncogenetics of Colorectal Cancer

Message from the Guest Editors

Colorectal carcinoma (CRC) is one of the most common cancers worldwide. It represents a heterogeneous group of disorders from a molecular genomic point of view. Sporadic CRC is the most common form and is associated with somatic mutations. DNA methylation. genomic instability in the form of copy number changes. and microsatellite instability. Inflammatory pathways and host immune response have been associated not only with pathogenesis but also targeted therapeutic options. Many of the changes occurring are also reflected in liquid biopsy samples. Full use of known and yet-to-beknown molecular changes in the tumor tissue and/or liquid biopsy for predictive, diagnostic, therapeutic, and prognostic purposes could improve personalized therapy. This Special Issue aims to focus on original research papers and review articles on different molecular genomic and epigenetic changes in CRC tissue and liquid biopsy and their association with the pathogenesis of CRC as well as therapeutic applications and outcomes.

Guest Editors

Dr. Muhammad Kibriya

1. Institute for Population and Precision Health (IPPH), Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA 2. Department of Public Health Sciences, Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA

Dr. Marc Bissonnette

Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL 60637, USA

Deadline for manuscript submissions

closed (31 December 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/192607

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

